Literature DB >> 2539173

Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11.

A Smith1, R Waibel, G Westera, A Martin, A T Zimmerman, R A Stahel.   

Abstract

We describe here a murine monoclonal antibody of the IgG2a isotype which was generated against the SW2 human small cell carcinoma cell line. The antibody, SWA11, was shown to bind to a partially defined antigen preferentially expressed on cell lines of small cell carcinoma origin. In vitro binding studies revealed 6.1 x 10(5) antigenic sites on the SW2 cell line and the Ka to be 1.2 x 10(9)M-1. Following injection into mice bearing 1-2 cm3 SW2 xenografts, SWA11 showed strong selective accumulation in the small cell heterotransplants with a tumour to blood ratio of 7.5:1 at day 4. Other tumour to organ ratios were similarly high at 19:1, 22:1 and 12:1 for liver, kidney and spleen respectively. The absolute amount of SWA11 which localised was 10.5% of total injected material per gram tumour at day 2 and this level did not markedly decrease by day 4. The high ability of SWA11 to localise to SCC xenografts was confirmed by external gamma scintigraphy. The potential application of SWA11 as a model system for in vivo radioimmunotherapy is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539173      PMCID: PMC2246986          DOI: 10.1038/bjc.1989.36

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas.

Authors:  R A Stahel; J A Speak; S D Bernal
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

Review 2.  Radioimmunotherapy of cancer: clinical studies and limiting factors.

Authors:  P W Dykes; A R Bradwell; C E Chapman; A T Vaughan
Journal:  Cancer Treat Rev       Date:  1987-06       Impact factor: 12.111

3.  Tumor-associated membrane sialoglycoprotein on human small cell lung carcinoma identified by the IgG2a monoclonal antibody SWA20.

Authors:  R Waibel; C J O'Hara; A Smith; R A Stahel
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

4.  Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody.

Authors:  R A Stahel; M Mabry; A T Skarin; J Speak; S D Bernal
Journal:  J Clin Oncol       Date:  1985-04       Impact factor: 44.544

5.  Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung.

Authors:  R A Stahel; C J O'Hara; M Mabry; R Waibel; K Sabbath; J A Speak; S D Bernal
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

6.  Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.

Authors:  A A Epenetos; A J Munro; S Stewart; R Rampling; H E Lambert; C G McKenzie; P Soutter; A Rahemtulla; G Hooker; G B Sivolapenko
Journal:  J Clin Oncol       Date:  1987-12       Impact factor: 44.544

7.  Radiolocalization of xenografted human lung cancer with monoclonal antibody 8 in nude mice.

Authors:  K Endo; H Kamma; T Ogata
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

8.  Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.

Authors:  R M Sharkey; M J Pykett; J A Siegel; E A Alger; F J Primus; D M Goldenberg
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

9.  Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies.

Authors:  C C Badger; K A Krohn; H Shulman; N Flournoy; I D Bernstein
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

10.  Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody.

Authors:  H M Smedley; P Finan; E S Lennox; A Ritson; F Takei; P Wraight; K Sikora
Journal:  Br J Cancer       Date:  1983-02       Impact factor: 7.640

View more
  14 in total

1.  Monoclonal antibodies defining the cluster-5A small cell lung carcinoma antigen.

Authors:  R Waibel; C J O'Hara; R A Stahel
Journal:  Br J Cancer Suppl       Date:  1991-06

2.  Polyclonal anti-idiotypic antibodies mimicking the small cell lung carcinoma antigen cluster-5A interact with a panel of antibodies and induce specific immune response in animals.

Authors:  C Zwicky; R A Stahel; H Jaksche; R Waibel; H P Lehmann; H Loibner
Journal:  Br J Cancer Suppl       Date:  1991-06

3.  Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer Suppl       Date:  1991-06

4.  Results of the central data analysis.

Authors:  P C Beverley; Y Olabiran; J A Ledermann; L G Bobrow; R L Souhami
Journal:  Br J Cancer Suppl       Date:  1991-06

5.  Modulation of neuroendocrine surface antigens in oncogene-activated small cell lung cancer lines.

Authors:  L A Doyle; M Mabry; R A Stahel; R Waibel; L H Goldstein
Journal:  Br J Cancer Suppl       Date:  1991-06

6.  Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis.

Authors:  A T Myklebust; K Beiske; A Pharo; C D Davies; S Aamdal; O Fodstad
Journal:  Br J Cancer Suppl       Date:  1991-06

7.  Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeast Pichia pastoris.

Authors:  Ulrike Giesübel; Benjamin Dälken; Hayat Mahmud; Winfried S Wels
Journal:  Biochem J       Date:  2006-03-15       Impact factor: 3.857

8.  Antibodies to the protein core of the small cell lung cancer workshop antigen cluster-w4 and to the leucocyte workshop antigen CD24 recognize the same short protein sequence leucine-alanine-proline.

Authors:  E Weber; H P Lehmann; A G Beck-Sickinger; E J Wawrzynczak; R Waibel; G Folkers; R A Stahel
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

9.  Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Authors:  Kathleen R Whiteman; Holly A Johnson; Michele F Mayo; Charlene A Audette; Christina N Carrigan; Alyssa LaBelle; Lawrence Zukerberg; John M Lambert; Robert J Lutz
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

10.  Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.

Authors:  E J Wawrzynczak; E J Derbyshire; R V Henry; G D Parnell; A Smith; R Waibel; R A Stahel
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.